The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy-Reference-Cited by-同舟云学术

The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

Published:2008-09-23 Issue:2 Volume:116 Page:303-309
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Zhang Yi,Sieuwerts Anieta M.,McGreevy Michelle,Casey Graham,Cufer Tanja,Paradiso Angelo,Harbeck Nadia,Span Paul N.,Hicks David G.,Crowe Joseph,Tubbs Raymond R.,Budd G. Thomas,Lyons Joanne,Sweep Fred C. G. J.,Schmitt Manfred,Schittulli Francesco,Golouh Rastko,Talantov Dmitri,Wang Yixin,Foekens John A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-008-0183-2.pdf

Reference25 articles.

1. Osborne CK, Yochmowitz MG, Knight WAIII, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46:2884–2888. doi:10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U

2. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529–1542. doi: 10.1093/jnci/88.21.1529

3. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858–868. doi: 10.1016/S0140-6736(04)16981-X

4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi: 10.1038/35021093

5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi: 10.1073/pnas.191367098

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine;Biotechnic & Histochemistry;2024-09-11

2. Early detection of breast cancer through the diagnosis of Nipple Aspirate Fluid (NAF);Clinical Proteomics;2024-06-28

3. NOTCH3 as a prognostic biomarker and its correlation with immune infiltration in gastrointestinal cancers;Scientific Reports;2024-06-21

4. Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues;eLife;2024-03-27

5. Exploration of Mechanisms of Drug Resistance in a Microfluidic Device and Patient Tissues;2024-02-28